Alzamend Neuro Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alzamend Neuro (ALZN).

Price Target Range — 5 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$26Upside to Avg. PT+1869.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 19, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$25→$26
Dec 22, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$42→$28
Sep 25, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$45→$42
Aug 21, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$180→$45
Mar 17, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$32→$20
Dec 16, 2024	Ascendiant Capital	Edward Woo	PT Cut	Buy	$35→$32
Nov 11, 2024	Ascendiant Capital	Edward Woo	PT Cut	Buy	$50→$35

More with Benzinga EdgeGet Access

Analyst Ratings News

Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts changed outlook on top names. Piper Sandler raises Mercury Systems' target price, Ascendiant Capital boosts Alzamend Neuro's target price, BTIG raises Henry Schein's target price, Cantor Fitzgerald increases Palo Alto's target price, Morgan Stanley cuts Baidu's target price, Cantor Fitzgerald slashes Crowdstrike Holdings' target price, Baird raises Donaldson Company's target price, B of A Securities cuts Pony AI's target price.

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raises the price target from $25 to $26.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $28

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $42 to $28.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ: ALZN) with a Buy and lowers the price target from $45 to $42.

Benzinga Newsdesk

Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $45

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $180 to $45.

Benzinga Newsdesk

Alzamend Neuro Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Alzamend Neuro Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $28

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42

Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $45

People Also Watch

People Also Watch

Alzamend Neuro Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Alzamend Neuro Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

PROAscendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26

PROAscendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $28

PROAscendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42

Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

PROAscendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $45

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $28

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $42

PRO
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $45